Barclays
GMAB icon

Barclays’s Genmab GMAB Stock Holding History

Barclays’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39K Sell
160
-1,979
-93% -$52.6K ﹤0.01% 4789
2026
Q1 		$57.4K Buy
2,139
+2,134
+42,680% +$64K ﹤0.01% 4264
2025
Q4 		$154 Hold
5
– – ﹤0.01% 5117
2025
Q3 		$153 Sell
5
-5,001
-100% -$122K ﹤0.01% 5255
2025
Q2 		$103K Buy
5,006
+1,852
+59% +$38K ﹤0.01% 4562
2025
Q1 		$61.8K Buy
3,154
+656
+26% +$13.8K ﹤0.01% 4565
2024
Q4 		$52.1K Buy
2,498
+2,285
+1,073% +$50.2K ﹤0.01% 4750
2024
Q3 		$5.19K Buy
213
+208
+4,160% +$5.56K ﹤0.01% 5028
2024
Q2 		$126 Sell
5
-61,000
-100% -$1.73M ﹤0.01% 4749
2024
Q1 		$1.82M Buy
61,005
+61,000
+1,220,000% +$1.79M ﹤0.01% 2645
2023
Q4 		$159 Sell
5
-5
-50% -$157 ﹤0.01% 5158
2023
Q3 		$352 Hold
10
– – ﹤0.01% 4517
2023
Q2 		$380 Buy
10
+5
+100% +$199 ﹤0.01% 4394
2023
Q1 		$189 Sell
5
-39,100
-100% -$1.5M ﹤0.01% 4983
2022
Q4 		$1.66M Buy
39,105
+100
+0.3% +$4.12K ﹤0.01% 2388
2022
Q3 		$1.25M Buy
39,005
+39,000
+780,000% +$1.37M ﹤0.01% 2059
2022
Q2 		$0 Sell
5
-46
-90% -$1.49K ﹤0.01% 5118
2022
Q1 		$2K Buy
+51
New +$1.75K ﹤0.01% 4782
2021
Q4 		– Sell
-9,650
Closed -$422K – 4364
2021
Q3 		$422K Buy
9,650
+58
+0.6% +$2.6K ﹤0.01% 3272
2021
Q2 		$392K Buy
9,592
+9,339
+3,691% +$360K ﹤0.01% 3208
2021
Q1 		$8K Buy
253
+207
+450% +$7.79K ﹤0.01% 4457
2020
Q4 		$2K Hold
46
– – ﹤0.01% 4814
2020
Q3 		$2K Hold
46
– – ﹤0.01% 5124
2020
Q2 		$2K Buy
+46
New +$1.25K ﹤0.01% 5448
2020
Q1 		– Sell
-121
Closed -$3K – 6250
2019
Q4 		$3K Sell
121
-4,062
-97% -$88.6K ﹤0.01% 6212
2019
Q3 		$84K Buy
+4,183
New +$82.4K ﹤0.01% 5603

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's GMAB Position: Q2 2026 in Review

Barclays reduced its Genmab (GMAB) stake by 93% in Q2 2026, selling an estimated $52.6K and leaving 160 shares worth $4.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4789.

Barclays first reported a position in GMAB in Q3 2019 and has held it in 26 quarters since. The position peaked at $1.82M in Q1 2024. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Barclays held 160 shares of Genmab worth $4.39K as of Q2 2026.
  • Barclays sold 1,979 Genmab shares in Q2 2026, an estimated $52.6K.
  • Genmab made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4789 holding.
  • Barclays first reported a position in Genmab in Q3 2019 and has held it in 26 quarters since.
  • Barclays's Genmab position peaked at $1.82M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.